Bradykinin B2 receptor Inhibitors
2 drugsAbout Bradykinin B2 receptor
The Bradykinin B2 receptor (B2R) is a G protein-coupled receptor activated by bradykinin, mediating vasodilation, inflammation, and pain.
B2R is a clinically validated drug target, though no genetic evidence directly links it to specific diseases.
Two FDA-approved small molecule drugs, FIRAZYR (Takeda) and ICATIBANT ACETATE (JIANGSU HANSOH PHARM), target B2R for other therapeutic areas.
Top Bradykinin B2 receptor Drugs
The competitive landscape includes two companies, Takeda and JIANGSU HANSOH PHARM, with approved B2R-targeting drugs.
Low market concentration suggests relatively low barriers to entry for new competitors.
Bradykinin B2 receptor Drug Modality Landscape
Modalities
Routes of Administration
Bradykinin B2 receptor is druggable by small molecules, though no oral formulations are currently approved.
The absence of other modalities suggests a whitespace opportunity for novel biologics targeting B2R.
Bradykinin B2 receptor Clinical Trials 14 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Bradykinin B2 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 5 | 3 | 1 | 1 | 75% |
| Phase 3 | 6 | 5 | 0 | 1 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Bradykinin B2 receptor Drug Approval Timeline (2011 - 2019)
The first drug was approved in 2011 (FIRAZYR), with the most recent approval in 2019 (ICATIBANT ACETATE).
The approval timeline indicates a slow but steady interest in B2R as a drug target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 6 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Bradykinin B2 receptor. A trial counts if an approved drug acting on Bradykinin B2 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.